First Action to Prevent Ammonia Production, Hyperammonemia, and Progressive Cognitive Decline
First Action to Prevent Ammonia Production, Hyperammonemia, and Progressive Cognitive Decline
The U.S. National Institutes of Health/National Institute on Aging (NIH/NIA) have invited CHELATEXX developers to apply for cognitive decline/Alzheimer's disease clinical trials research funding. This is a direct result of CHELATEXX's ability to absorb neurotoxic ammonia, from dysbiosis, abnormal colonic microbiome. This was proven in our preclinical Beagle Dog Study of hyperammonemia prevention with oral activated charcoal, reducing serum ammonia by 39% and 49%.
"Changes in Human Microbiome Precede Alzheimers Cognitive Declines"
(NIH April 2023) Drs Rimsha Ali and Shivaraj Nagalli
In 1985, Dr Fisman et al reported "Postprandial blood ammonia levels were significantly higher in 22 patients with Alzheimer's disease than 37 control subjects"
Normal blood levels in adults below 50 micrograms/dl. Hyperammonemia above 50 micrograms/dl.
Alzheimer's disease patients.........68.8 micrograms/dl of blood ammonia
Hospital control patients.............44.8 micrograms/dl of blood ammonia
Community control patients.........46.2 micrograms/dl of blood ammonia
Sign up for updates from CHELATEXX.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.